Balázs Ács, Associate Professor at Karolinska Institutet, shared a post on LinkedIn:
“New publication in Annals of Oncology!
Our international collaboration reports on the impact of integrating tumor‑infiltrating lymphocytes (TILs) into the PREDICT prognostic model for patients with triple‑negative breast cancer (TNBC). The study involving 3698 early-stage TNBC patients shows that incorporating TILs provides greater clinical utility in identifying low-risk patients who may safely forgo chemotherapy, reinforcing the clinical relevance of pathologist-read TILs assessment.
It’s great to see how pathology‑driven biomarkers continue to inform precision oncology and support more individualized treatment decisions for patients with triple negative breast cancer.
I’m glad that I could participate in the study. Huge congratulations to all the authors, especially who initiated and led the study. This study wouldn’t have been possible without the International Immuno-Oncology Biomarker Working Group. We need such collaborations in cancer research.”
Title: Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival
Authors: Y. Wang, D. Drubay, S.F. Jonas, S. Loi, S. Michiels
Read the article here.
